West Pharmaceutical
637 hedge funds and large institutions have $16.2B invested in West Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 231 increasing their positions, 232 reducing their positions, and 78 closing their positions.
13% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 78
0.68% more ownership
Funds ownership: 92.7% → 93.38% (+0.68%)
0% less funds holding
Funds holding: 638 → 637 (-1)
0% less repeat investments, than reductions
Existing positions increased: 231 | Existing positions reduced: 232
4% less capital invested
Capital invested by funds: $16.9B → $16.2B (-$687M)
4% less call options, than puts
Call options by funds: $29.8M | Put options by funds: $31.2M
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$440M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$108M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$93.1M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$87.8M |
| 5 |
Two Sigma Investments
New York
|
+$78.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$372M |
| 2 |
WCM Investment Management
Laguna Beach,
California
|
-$311M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$122M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$79.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$49.7M |
WST Hedge Fund Activity: Q4 2022 in Review
637 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2022, worth a combined $16.2B — down 4.1% from $16.9B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new WST positions and 78 closed out — a net gain of 10 holders — while 231 added to existing stakes and 232 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $440M. The largest seller was T. Rowe Price Associates, cutting an estimated $372M.
- 637 institutional investors held West Pharmaceutical (WST) as of Q4 2022, down from 638 in Q3 2022.
- Funds reported $16.2B of West Pharmaceutical stock for Q4 2022, down 4.1% quarter-over-quarter.
- 88 funds opened new West Pharmaceutical positions in Q4 2022 and 78 closed out, a net change of +10 holders.
- The largest West Pharmaceutical buyer in Q4 2022 was Bank of New York Mellon, an estimated $440M added.
- The largest West Pharmaceutical seller in Q4 2022 was T. Rowe Price Associates, an estimated $372M sold.
Based on aggregated 13F filings for Q4 2022.